NCT05450705View on ClinicalTrials.gov

V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,500

Participants

Timeline

Start Date

July 22, 2022

Primary Completion Date

August 3, 2029

Study Completion Date

August 3, 2029

Conditions
Papillomavirus Infections
Interventions
BIOLOGICAL

9vHPV vaccine

A 9-valent HPV vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) will be administered as a 0.5 mL IM injection.

Trial Locations (2)

317600

Yuhuan Center for Disease Control and Prevention ( Site 0002), Taizhou

324100

Jiangshan Center for Disease Control and Prevention ( Site 0001), Quzhou

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY